Form 4: Eledon Director Converts RSUs to Common Stock

Eledon Pharmaceuticals Director James A. Robinson Jr. acquired 3,430 shares of common stock through the settlement of restricted stock units.

Summary

• James A. Robinson Jr., a Director of Eledon Pharmaceuticals, Inc. (ELDN), reported a transaction involving the company's common stock.
• On January 10, 2026, Robinson acquired 3,430 shares of common stock.
• This acquisition resulted from the settlement of restricted stock units (RSUs) on a one-for-one basis.
• The RSUs were granted on January 10, 2025, and vested 100% on January 10, 2026.
• Following this transaction, Robinson directly beneficially owns 3,430 shares of common stock.

Sentiment

Score: 7

Explanation: The settlement of restricted stock units increases the director's direct ownership in the company, which generally aligns management's interests with shareholders. However, it is a pre-scheduled compensation event rather than a discretionary open-market purchase.

Positives

• Director James A. Robinson Jr. increased his direct beneficial ownership of Eledon Pharmaceuticals common stock by 3,430 shares.
• The settlement of restricted stock units (RSUs) indicates a vesting event, aligning the director's interests with long-term shareholder value.

Negatives

• The transaction involved the settlement of previously granted restricted stock units at a price of $0, rather than an open market purchase with personal capital.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider transactions, such as the settlement of restricted stock units, are common occurrences in publicly traded companies. They provide insight into management's direct ownership and alignment with shareholder interests, though RSU settlements are typically compensation-related rather than discretionary open-market purchases.

Comparison to Industry Standards

• Not applicable. This Form 4 reports a standard RSU vesting and settlement for a director, which is a common compensation practice across industries. There are no specific comparable companies, projects, or results to detail in this context.

Related Party Transactions

• The transaction involves a director and the company, which is a related party transaction in the context of compensation, but no other specific related party dealings are disclosed beyond the RSU settlement.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director can be viewed positively as it aligns the director's financial interests with those of other shareholders.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Eledon Pharmaceuticals, ELDN, Form 4, Insider Transaction, Restricted Stock Units, RSU Settlement, Director Ownership, Common Stock